1) Matsuo H, Nakamura T, Tsujihata M, et al:Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy. Lancet 1988;2(8620):1109-13 2) Itoyama Y, Minato S, Kira J, et al:Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology 1988;38:1302-7 3) Matsuo H, Nakamura T, Tsujihata M, et al:Human T-lymphotropic virus type I (HTLV-I) associated myelopathy in Nagasaki:clinical features and treatment of 21 cases. Jpn J Med 1989;28:328-34 4) Oishi M, Mochizuki Y, Hara M, et al:Human T-lymphotropic virus type I associated myelopathy treated effectively with lymphocytapheresis using a leukocyte removal filter. Intern Med 1995;34:1215-9 5) Nakagawa M, Nakahara K, Maruyama Y, et al:Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 1996;2:345-55 6) Osame M, Nakagawa M, Umehara F, et al:Recent studies on the epidemiology, clinical features and pathogenic mechanisms of HTLV-I associated myelopathy (HAM/TSP) and other diseases associated to HTLV. J Neurovirol 1997;3:S50-1 7) Gessain A, Mahieux R:Tropical spastic paraparesis and HTLV-1 associated myelopathy:clinical, epidemiological, virological and therapeutic aspects. Rev Neurol (Paris) 2012;168:257-69 8) Narukawa N, Shiizaki K, Kitabata Y, et al:Plasma exchange for the treatment of human T-cell lymphotropic virus type 1 associated myelopathy. Ther Apher 2001;5:491-3
